Andrea Wasilewski, MD
Neurology · Rochester, NYNPI 1861802837
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.9%), speaking fees and grants — rather than concentrated in one kind of arrangement. Novocure Inc. accounts for 95.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $12,621 and has fallen 94.9% since, to $643 in 2025.
Across 29 payments — averaging $790.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$22K
- Sanofi$1K
- Jazz Pharmaceuticals Inc.$26
Across 42 payments — averaging $6576.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure GmbH$251K
- GT Medical Technologies, Inc$25K
What the payments were for
- Consulting fees$10,75847%
- Speaking & faculty fees$9,70042%
- Grants$1,0004%
- Travel & lodging$8074%
- Food & beverage$6593%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 27 | $21,898 |
| Sanofi | 1 | $1,000 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optune$12,298
- Oncology$2,500
- NO PRODUCT DISCUSSED$1,000
- Optune Gio$583
How this compares
$22,924 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 79 | $2,143 |
| Lacosamide | 18 | $1,059 |
| Dexamethasone | 53 | $835 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 27 | $215 |
| Ondansetron Hcl | 29 | $200 |
| Famotidine | 27 | $171 |
| Sertraline Hcl | 16 | $139 |
| Baclofen | 14 | $101 |
| Lisinopril | 17 | $90 |
| Omeprazole | 12 | $86 |
| Pantoprazole Sodium | 12 | $49 |
| Prednisone | 16 | $40 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $39 |
Paid to pharmacies, not to this prescriber.
Other neurology in Rochester
- Jacob DominikRochester$216K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.